Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 31.18 as of 2026-10-06T13:45:52.441Z.
Consensus retrieved: 2026-10-06T09:40:46.162Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:45:52.441Z.
Quote observation: 2026-10-06T13:45:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bfcb3301ea88d81669eff773e5fd2db5a769ce8965017b8c125060594f905b9e
Forward PE Ratio (31.18) = Dated Quote Price ($66.16) / Consensus Forward EPS ($2.12)
FORWARD PE RATIO
31.18
SECTOR MEDIAN · HEALTHCARE
19.20
median of 146 covered companies
CURRENT VS SECTOR MEDIAN
+62.44%
vs the sector median at left
Bruker Corporation
Market Cap
$10.07B
Forward PE Ratio
31.18
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bruker Corporation (BRKR) | $10.07B | 31.18 |
| Molina Healthcare, Inc. (MOH)vs › | $10.15B | N/A |
| The Ensign Group, Inc. (ENSG)vs › | $9.96B | 21.93 |
| Align Technology, Inc. (ALGN)vs › | $10.26B | 12.69 |
| Henry Schein, Inc. (HSIC)vs › | $9.82B | 16.01 |
| Globus Medical, Inc. (GMED)vs › | $10.37B | 15.37 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.72B | 43.34 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.44B | 39.80 |
| Universal Health Services, Inc. (UHS)vs › | $10.57B | 7.74 |
| Bruker Corporation (BRKRP)vs › | $9.57B | 224.71 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
31.2
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $66.16, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.12 | $2.11 – $2.15 | 6 | 31.2x |
| 2027-12-31 | $2.40 | $2.32 – $2.50 | 6 | 27.6x |
| 2028-12-31 | $2.79 | $2.55 – $3.03 | 2 | 23.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
